The global Preeclampsia Diagnostics Market Growth Accelerated by Early Detection and Screening

Preeclampsia is a pregnancy complication characterized by high blood pressure and presence of protein in the urine, which can be dangerous for both mother and baby if not diagnosed and treated on time. Rapid diagnosis of preeclampsia is important as it allows close monitoring and timely medical intervention in severe cases.

The global Preeclampsia Diagnostics Market is estimated to be valued at US$ 1.2 Billion in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The demand for preeclampsia diagnostic products is expected to grow rapidly during the forecast period, driven by increasing focus on early detection of the condition through prescreening and diagnostic tests. Significant& research activities are underway to develop novel biomarkers and diagnostic tools that can accurately detect preeclampsia at an early stage of pregnancy. This is important as early detection allows timely management of condition as well as reduces health risks for both mother and baby. Development of advanced diagnostic tools with high sensitivity and the ability to screen at an early gestation week will further support the growth of this market over the coming years.

Segment Analysis

The Global preeclampsia diagnostics market size is dominated by the blood testing sub-segment. This sub-segment holds nearly 60% of the market share owing to the increased adoption of blood testing for the diagnosis of preeclampsia. Blood testing involves minimal invasive procedures and provides accurate results for the diagnosis of preeclampsia. Therefore, blood testing is preferred by healthcare professionals as the preferred diagnostic test for preeclampsia screening and monitoring.

Key Takeaways

The global preeclampsia diagnostics market is expected to witness high growth over the forecast period of 2023 to 2030. The global Preeclampsia Diagnostics Market is estimated to be valued at US$ 1.2 Billion in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030.

Regional analysis

North America dominated the global preeclampsia diagnostics market in 2022, accounting for over 35% of the market share. Rising awareness regarding preeclampsia diagnosis and presence of advanced healthcare facilities are major factors responsible for North America's dominance. However, Asia Pacific is expected to witness the fastest growth over the forecast period supported by growing healthcare spending, rising medical tourism, and increasing government initiatives to spread awareness regarding preeclampsia.

Key players
Key players operating in the preeclampsia diagnostics market are Siemens Healthineers, Roche Diagnostics, Bayer, Abbott Laboratories, BD, and Thermo Fisher Scientific. Siemens Healthineers holds the leading market position owing to its robust product portfolio for preeclampsia diagnosis that includes laboratory testing solutions and POC diagnostic devices for fast detection of the condition.

Get More Insights On This Topic: https://www.newsstatix.com/preeclampsia-diagnostics-market-size-share-analysis-2023-2030/